Epstein-Barr virus peptide-HLA class I complex

The Epstein-Barr virus peptide-HLA class I complex is formed when cytosolic peptides generated from EBV proteins are loaded into the peptide binding groove of HLA class I molecules (encoded by HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-G)[1][2]. The complex is displayed on the surface of infected cells, presenting viral antigenic determinants to cytotoxic CD8+ T cells for immune recognition. This system is crucial for both clearance of EBV infection and for immunosurveillance preventing EBV-driven malignancies[1][3][6]. EBV has evolved several proteins to downregulate HLA class I presentation and evade immune responses, highlighting the ongoing arms race between host immunity and viral survival[1]. Therapeutic interventions target this complex in efforts to stimulate or restore CD8+ T cell-mediated immunity, and its role as a disease biomarker and vaccine target is increasingly recognized[6]. The specificity and strength of the immune response critically depend on both the HLA allele and the presented peptide[2][3][6].

Other names

EBV epitope-HLA class I complexMHC class I-presented EBV peptideEpstein-Barr virus antigen-HLA class I complex

Activation of cytotoxic T lymphocytes (CD8+ T cells) via recognition of EBV peptides presented by HLA class I Enhancement of immune clearance of infected or malignant cells Some drugs or vaccines aim to increase density or immunogenicity of specific EBV peptide-HLA complexes